<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
<channel>
<title>Neurocrine Biosciences Inc — News on 6ix</title>
<link>https://6ix.com/company/neurocrine-biosciences-inc</link>
<description>Latest news and press releases for Neurocrine Biosciences Inc on 6ix.</description>
<language>en-us</language>
<lastBuildDate>Wed, 29 Apr 2026 20:05:00 GMT</lastBuildDate>
<generator>6ix RSS</generator>
<atom:link href="https://6ix.com/rss/company/neurocrine-biosciences-inc" rel="self" type="application/rss+xml" />
<image>
<url>https://6ix-events-pro.s3.amazonaws.com/6ixvideo/logos/org-logo6835a0a878dffbe2df108f93.webp</url>
<title>Neurocrine Biosciences Inc</title>
<link>https://6ix.com/company/neurocrine-biosciences-inc</link>
</image>
<item>
<title>Neurocrine Biosciences Announces Publication Establishing Clinically Meaningful Improvement Threshold for the Tardive Dyskinesia Impact Scale</title>
<link>https://6ix.com/company/neurocrine-biosciences-inc/news/neurocrine-biosciences-announces-publication-establishing-clinically-meaningful-improvement-threshold-for-the-tardive-dyskinesia-impact-scale</link>
<guid isPermaLink="true">https://6ix.com/company/neurocrine-biosciences-inc/news/neurocrine-biosciences-announces-publication-establishing-clinically-meaningful-improvement-threshold-for-the-tardive-dyskinesia-impact-scale</guid>
<pubDate>Wed, 29 Apr 2026 20:05:00 GMT</pubDate>
<description>Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced the publication of new peer-reviewed research in The Journal of Clinical Psychiatry demonstrating how the Tardive Dyskinesia Impact Scale helps characterize patient-reported burden in tardive dyskinesia and has been used in clinical studies to assess meaningful improvement over the course of treatment with INGREZZA® (valbenazine) capsules.</description>
</item>
<item>
<title>Neurocrine Biosciences Presents New Two-Year CRENESSITY® (crinecerfont) Data Showing Sustained Glucocorticoid Dose Reductions While Maintaining Androgen Control in Adults with Classic Congenital Adrenal Hyperplasia</title>
<link>https://6ix.com/company/neurocrine-biosciences-inc/news/neurocrine-biosciences-presents-new-two-year-crenessityr-crinecerfont-data-showing-sustained-glucocorticoid-dose-reductions-while-maintaining-androgen-control-in-adults-with-classic-congenital-adrenal-hyperplasia</link>
<guid isPermaLink="true">https://6ix.com/company/neurocrine-biosciences-inc/news/neurocrine-biosciences-presents-new-two-year-crenessityr-crinecerfont-data-showing-sustained-glucocorticoid-dose-reductions-while-maintaining-androgen-control-in-adults-with-classic-congenital-adrenal-hyperplasia</guid>
<pubDate>Wed, 22 Apr 2026 20:05:00 GMT</pubDate>
<description>Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced the first presentation of new two-year data from the Phase 3 CAHtalyst® Adult study demonstrating sustained, substantial reductions in glucocorticoid (GC) doses in adults with classic congenital adrenal hyperplasia treated with CRENESSITY® (crinecerfont), with approximately 70% of patients achieving GC doses within the physiologic range. These data build upon previously reported one-year results and were presented at the American Associ</description>
</item>
<item>
<title>Neurocrine Biosciences Presents First Real-World Head-to-Head Claims Analysis Demonstrating Greater Treatment Persistence with INGREZZA® (valbenazine) Capsules Compared to AUSTEDO XR</title>
<link>https://6ix.com/company/neurocrine-biosciences-inc/news/neurocrine-biosciences-presents-first-real-world-head-to-head-claims-analysis-demonstrating-greater-treatment-persistence-with-ingrezzar-valbenazine-capsules-compared-to-austedo-xr</link>
<guid isPermaLink="true">https://6ix.com/company/neurocrine-biosciences-inc/news/neurocrine-biosciences-presents-first-real-world-head-to-head-claims-analysis-demonstrating-greater-treatment-persistence-with-ingrezzar-valbenazine-capsules-compared-to-austedo-xr</guid>
<pubDate>Tue, 14 Apr 2026 12:30:00 GMT</pubDate>
<description>Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced the presentation of new real-world evidence demonstrating that adult patients with tardive dyskinesia receiving INGREZZA® (valbenazine) capsules showed higher treatment persistence compared to those on AUSTEDO XR (deutetrabenazine). The findings are being presented at the Academy of Managed Care Pharmacy 2026 Annual Meeting in Nashville.</description>
</item>
<item>
<title>Neurocrine Biosciences Announces Conference Call and Webcast of First Quarter 2026 Financial Results</title>
<link>https://6ix.com/company/neurocrine-biosciences-inc/news/neurocrine-biosciences-announces-conference-call-and-webcast-of-first-quarter-2026-financial-results</link>
<guid isPermaLink="true">https://6ix.com/company/neurocrine-biosciences-inc/news/neurocrine-biosciences-announces-conference-call-and-webcast-of-first-quarter-2026-financial-results</guid>
<pubDate>Tue, 14 Apr 2026 04:00:00 GMT</pubDate>
<description>Conference Call and Webcast Scheduled for Tuesday, May 5SAN DIEGO, April 14, 2026 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) announced today</description>
</item>
<item>
<title>Nxera Pharma’s Partner Neurocrine Biosciences Doses First Patient in Phase 2 Trial of NBI-1117570 for Adults with Schizophrenia</title>
<link>https://6ix.com/company/neurocrine-biosciences-inc/news/nxera-pharmas-partner-neurocrine-biosciences-doses-first-patient-in-phase-2-trial-of-nbi-1117570-for-adults-with-schizophrenia</link>
<guid isPermaLink="true">https://6ix.com/company/neurocrine-biosciences-inc/news/nxera-pharmas-partner-neurocrine-biosciences-doses-first-patient-in-phase-2-trial-of-nbi-1117570-for-adults-with-schizophrenia</guid>
<pubDate>Sun, 12 Apr 2026 23:30:00 GMT</pubDate>
<description>NBI-1117570 is an investigational oral, dual muscarinic M1/M4 selective receptor agonist discovered by Nxera advancing through clinical development under a multi-program collaboration with NeurocrineNxera to receive US$22.5 million in milestone payments from Neurocrine Tokyo, Japan and Cambridge, UK, 13 April 2026 – Nxera Pharma Co., Ltd. (“Nxera” or “the Company”; TSE 4565) today announces that its partner Neurocrine Biosciences Inc. (“Neurocrine”) has initiated and dosed the first patient(s) i</description>
</item>
<item>
<title>Neurocrine to Acquire Soleno Therapeutics, Expanding Its Endocrinology and Rare Disease Portfolio</title>
<link>https://6ix.com/company/neurocrine-biosciences-inc/news/neurocrine-to-acquire-soleno-therapeutics-expanding-its-endocrinology-and-rare-disease-portfolio</link>
<guid isPermaLink="true">https://6ix.com/company/neurocrine-biosciences-inc/news/neurocrine-to-acquire-soleno-therapeutics-expanding-its-endocrinology-and-rare-disease-portfolio</guid>
<pubDate>Mon, 06 Apr 2026 04:00:00 GMT</pubDate>
<description>VYKAT™ XR (diazoxide choline) is the First and Only FDA Approved Treatment for Hyperphagia in Prader-Willi Syndrome and Represents a Transformative Therapy</description>
</item>
<item>
<title>Neurocrine Biosciences Presents First Expert Consensus Recommendations for Tardive Dyskinesia in Long-Term Care Settings</title>
<link>https://6ix.com/company/neurocrine-biosciences-inc/news/neurocrine-biosciences-presents-first-expert-consensus-recommendations-for-tardive-dyskinesia-in-long-term-care-settings</link>
<guid isPermaLink="true">https://6ix.com/company/neurocrine-biosciences-inc/news/neurocrine-biosciences-presents-first-expert-consensus-recommendations-for-tardive-dyskinesia-in-long-term-care-settings</guid>
<pubDate>Thu, 26 Mar 2026 04:00:00 GMT</pubDate>
<description>Expert panel establishes structured approach to tardive dyskinesia screening, diagnosis and treatment in long-term care, including use of VMAT2 inhibitorsNew</description>
</item>
<item>
<title>Neurocrine Biosciences Appoints Andrew Ratz, Ph.D., as Chief Technical Operations Officer</title>
<link>https://6ix.com/company/neurocrine-biosciences-inc/news/neurocrine-biosciences-appoints-andrew-ratz-phd-as-chief-technical-operations-officer</link>
<guid isPermaLink="true">https://6ix.com/company/neurocrine-biosciences-inc/news/neurocrine-biosciences-appoints-andrew-ratz-phd-as-chief-technical-operations-officer</guid>
<pubDate>Tue, 17 Mar 2026 04:00:00 GMT</pubDate>
<description>SAN DIEGO, March 17, 2026 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced the promotion of Andrew Ratz, Ph.D., to the executive</description>
</item>
<item>
<title>Neurocrine Biosciences to Present at the Stifel 2026 Virtual CNS Forum</title>
<link>https://6ix.com/company/neurocrine-biosciences-inc/news/neurocrine-biosciences-to-present-at-the-stifel-2026-virtual-cns-forum-31</link>
<guid isPermaLink="true">https://6ix.com/company/neurocrine-biosciences-inc/news/neurocrine-biosciences-to-present-at-the-stifel-2026-virtual-cns-forum-31</guid>
<pubDate>Tue, 10 Mar 2026 04:00:00 GMT</pubDate>
<description>SAN DIEGO, March 10, 2026 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced that members of the management team will participate at</description>
</item>
<item>
<title>Neurocrine Biosciences Reports Fourth-Quarter and Full-Year 2025 Financial Results and Provides Financial Expectations for 2026</title>
<link>https://6ix.com/company/neurocrine-biosciences-inc/news/neurocrine-biosciences-reports-fourth-quarter-210100814</link>
<guid isPermaLink="true">https://6ix.com/company/neurocrine-biosciences-inc/news/neurocrine-biosciences-reports-fourth-quarter-210100814</guid>
<pubDate>Wed, 11 Feb 2026 21:01:00 GMT</pubDate>
<description>Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced its financial results for the fourth quarter ended December 31, 2025.</description>
</item>
<item>
<title>Neurocrine Biosciences Initiates Phase 2 Clinical Study Evaluating NBI-1065890 in Adults with Tardive Dyskinesia</title>
<link>https://6ix.com/company/neurocrine-biosciences-inc/news/neurocrine-biosciences-initiates-phase-2-133000398</link>
<guid isPermaLink="true">https://6ix.com/company/neurocrine-biosciences-inc/news/neurocrine-biosciences-initiates-phase-2-133000398</guid>
<pubDate>Mon, 26 Jan 2026 13:30:00 GMT</pubDate>
<description>Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced the initiation of its Phase 2 clinical study of investigational compound NBI-1065890 in adults with tardive dyskinesia (TD). NBI-1065890 is a next-generation, selective inhibitor of the vesicular monoamine transporter 2 (VMAT2). Building on nearly 20 years of deep scientific expertise and experience in VMAT2 inhibition, Neurocrine designed NBI-1065890 to potentially deliver a differentiated profile, including the possibility of longer-a</description>
</item>
<item>
<title>Neurocrine Biosciences Announces Conference Call and Webcast of Fourth Quarter and Year-End 2025 Financial Results</title>
<link>https://6ix.com/company/neurocrine-biosciences-inc/news/neurocrine-biosciences-announces-conference-call-210100282</link>
<guid isPermaLink="true">https://6ix.com/company/neurocrine-biosciences-inc/news/neurocrine-biosciences-announces-conference-call-210100282</guid>
<pubDate>Wed, 21 Jan 2026 21:01:00 GMT</pubDate>
<description>Neurocrine Biosciences, Inc. (Nasdaq: NBIX) announced today that it has scheduled its fourth quarter and year-end 2025 financial results conference call and webcast for 1:30 p.m. Pacific Time (4:30 p.m. Eastern Time) on February 11, 2026.</description>
</item>
<item>
<title>Neurocrine Biosciences Presents Head-to-Head INGREZZA® (valbenazine) Capsules Data Demonstrating Higher VMAT2 Target Occupancy Compared to AUSTEDO XR</title>
<link>https://6ix.com/company/neurocrine-biosciences-inc/news/neurocrine-biosciences-presents-head-head-133000195</link>
<guid isPermaLink="true">https://6ix.com/company/neurocrine-biosciences-inc/news/neurocrine-biosciences-presents-head-head-133000195</guid>
<pubDate>Thu, 15 Jan 2026 13:30:00 GMT</pubDate>
<description>Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced the presentation of the first head-to-head data comparing vesicular monoamine transporter 2 (VMAT2) target occupancy between INGREZZA® (valbenazine) capsules and AUSTEDO XR (deutetrabenazine) at therapeutic doses. Results from the study confirmed that both compounds engage VMAT2; however, INGREZZA demonstrated significantly higher VMAT2 target occupancy and greater potency. Findings were presented at the American College of Neuropsychop</description>
</item>
<item>
<title>Neurocrine Biosciences to Present at the 44th Annual J.P. Morgan Healthcare Conference</title>
<link>https://6ix.com/company/neurocrine-biosciences-inc/news/neurocrine-biosciences-present-44th-annual-jp-morgan-healthcare-conference-2026-01-05</link>
<guid isPermaLink="true">https://6ix.com/company/neurocrine-biosciences-inc/news/neurocrine-biosciences-present-44th-annual-jp-morgan-healthcare-conference-2026-01-05</guid>
<pubDate>Mon, 05 Jan 2026 05:00:00 GMT</pubDate>
<description>SAN DIEGO, Jan. 5, 2026 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) will present at the 44th Annual J.P. Morgan Healthcare Conference at 9:45</description>
</item>
<item>
<title>Neurocrine Biosciences Provides Update on Phase 3 Study of Valbenazine in Dyskinetic Cerebral Palsy</title>
<link>https://6ix.com/company/neurocrine-biosciences-inc/news/neurocrine-biosciences-provides-update-phase-3-study-valbenazine-dyskinetic-cerebral</link>
<guid isPermaLink="true">https://6ix.com/company/neurocrine-biosciences-inc/news/neurocrine-biosciences-provides-update-phase-3-study-valbenazine-dyskinetic-cerebral</guid>
<pubDate>Mon, 22 Dec 2025 05:00:00 GMT</pubDate>
<description>SAN DIEGO, Dec. 22, 2025 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced that its Phase 3 KINECT®-DCP study evaluating the</description>
</item>
<item>
<title>Neurocrine Biosciences Showcases R&D Transformation Driving Innovation Across Neuroscience and Endocrinology</title>
<link>https://6ix.com/company/neurocrine-biosciences-inc/news/neurocrine-biosciences-showcases-rd-transformation-driving-innovation-across</link>
<guid isPermaLink="true">https://6ix.com/company/neurocrine-biosciences-inc/news/neurocrine-biosciences-showcases-rd-transformation-driving-innovation-across</guid>
<pubDate>Tue, 16 Dec 2025 05:00:00 GMT</pubDate>
<description>Provided Update on R&D Engine Now On Track to Deliver Multiple First- and Best-in-Class Medicines, Positioning Company for Long-Term Value Creation Across</description>
</item>
<item>
<title>Neurocrine Biosciences to Host R&D Day on December 16</title>
<link>https://6ix.com/company/neurocrine-biosciences-inc/news/neurocrine-biosciences-host-rd-day-december-16-2025-12-09</link>
<guid isPermaLink="true">https://6ix.com/company/neurocrine-biosciences-inc/news/neurocrine-biosciences-host-rd-day-december-16-2025-12-09</guid>
<pubDate>Tue, 09 Dec 2025 05:00:00 GMT</pubDate>
<description>SAN DIEGO, Dec. 9, 2025 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced that it will hold its 2025 R&D Day on Tuesday, December</description>
</item>
<item>
<title>Neurocrine Biosciences Announces Publication of Landmark Narrative Review on FDA-Approved VMAT2 Inhibitors Demonstrating Unique Profile of INGREZZA® (valbenazine) Capsules</title>
<link>https://6ix.com/company/neurocrine-biosciences-inc/news/neurocrine-biosciences-announces-publication-landmark-narrative-review-fda-approved</link>
<guid isPermaLink="true">https://6ix.com/company/neurocrine-biosciences-inc/news/neurocrine-biosciences-announces-publication-landmark-narrative-review-fda-approved</guid>
<pubDate>Thu, 20 Nov 2025 05:00:00 GMT</pubDate>
<description>Published, peer-reviewed narrative review in CNS Spectrums compiles pharmacologic, pharmacokinetic and clinical data of VMAT2 inhibitors to highlight</description>
</item>
<item>
<title>Neurocrine Biosciences to Present at Upcoming Investor Conferences</title>
<link>https://6ix.com/company/neurocrine-biosciences-inc/news/neurocrine-biosciences-present-upcoming-investor-conferences-2025-11-11</link>
<guid isPermaLink="true">https://6ix.com/company/neurocrine-biosciences-inc/news/neurocrine-biosciences-present-upcoming-investor-conferences-2025-11-11</guid>
<pubDate>Tue, 11 Nov 2025 05:00:00 GMT</pubDate>
<description>SAN DIEGO, Nov. 11, 2025 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced that members of the management team will participate at</description>
</item>
<item>
<title>Neurocrine Biosciences Provides Update on Phase 2 Study of NBI-1070770 in Adults with Major Depressive Disorder</title>
<link>https://6ix.com/company/neurocrine-biosciences-inc/news/neurocrine-biosciences-provides-update-phase-2-study-nbi-1070770-adults-major</link>
<guid isPermaLink="true">https://6ix.com/company/neurocrine-biosciences-inc/news/neurocrine-biosciences-provides-update-phase-2-study-nbi-1070770-adults-major</guid>
<pubDate>Mon, 10 Nov 2025 05:00:00 GMT</pubDate>
<description>SAN DIEGO, Nov. 10, 2025 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced that its Phase 2 study evaluating the efficacy, safety</description>
</item>
</channel>
</rss>